Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  SciClone Pharmaceuticals, Inc.    SCLN

Delayed Quote. Delayed  - 07/29 10:00:00 pm
10.56 USD   +1.44%
07/28 SCICLONE PHARMA : To Report Second Quarter 2016 Financial Results On..
07/19 TUESDAY SECTOR : Non-Precious Metals & Non-Metallic Mining, Drugs
07/19 SCICLONE PHARMA : Provides Update On Strategic Review Process
News SummaryMost relevantAll newsSector news 

SciClone to Restate Results for Certain Periods on China Accounting Errors

share with twitter share with LinkedIn share with facebook
share via e-mail
02/22/2013 | 11:05pm CEST
   By Debbie Cai 

SciClone Pharmaceuticals Inc. (>> SciClone Pharmaceuticals, Inc.) said it will restate its financial statements for certain periods in 2012 and 2011 due mainly to accounting errors at a Chinese subsidiary.

Shares slid 6.2% to $4.52 after hours Friday. The stock is up 12% so far this year.

Chinese drugmaker NovaMed Pharmaceuticals Inc., which SciClone acquired in April 2011, made accounting errors pertaining to the timing of Pfizer Inc. (>> Pfizer Inc.) product-revenue recognition and the recognition of product-return reserves as to antiplatelet drug Aggrastat.

The company will restate financial statements for the first, second and third quarters of last year, the second and third quarters of 2011, and for the full 2011.

SciClone Chief Executive Friedhelm Blobel said the decision to restate financials, which is expected to increase the company's 2012 revenue and earnings and decrease that of 2011, was made after careful review of available facts.

The company believes the changes will raise its revenue for the first nine months of last year by about $3 million, and increase its profit before income taxes by about $2 million. The changes for the full 2011 will lower revenue by about $1 million and decrease income by less than $1 million.

SciClone also said the goodwill related to the acquisition of NovaMed will be increased by approximately $2 million. The restatements wouldn't impact previously reported cash or cash equivalents balances, the company said.

The company said it plans to amend its 2011 10-K form and other relevant filings as soon as reasonably practicable.

Last November, SciClone said it swung to a third-quarter loss as the company works to address issues across its China organization, some of which might have affected sales of its lead drug Zadaxin.

Write to Debbie Cai at debbie.cai@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SciClone Pharmaceuticals, Inc., Pfizer Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
07/28 SCICLONE PHARMACEUTICALS : To Report Second Quarter 2016 Financial Results On Au..
07/19 TUESDAY SECTOR LAGGARDS : Non-Precious Metals & Non-Metallic Mining, Drugs
07/19 SCICLONE PHARMACEUTICALS : Provides Update On Strategic Review Process
06/15 SCICLONE PHARMACEUTICALS INC : Change in Directors or Principal Officers, Submis..
06/14 SCICLONE PHARMACEUTICALS INC. : (SCLN) Jumps 5.36% on June 13
05/19 SCICLONE PHARMACEUTICALS : Reports First Quarter 2016 Financial Results
05/10 SCICLONE PHARMACEUTICALS INC : Results of Operations and Financial Condition, Fi..
05/10 SCICLONE PHARMACEUTICALS : posts 1Q profit
05/10 SCICLONE PHARMACEUTICALS : Reports First Quarter 2016 Financial Results
05/05 SCICLONE PHARMACEUTICALS : To Report First Quarter 2016 Financial Results On May..
More news
Sector news : Pharmaceuticals - NEC
08:48aDJMERCK : Earnings Watch -- WSJ
01:14a BAYER : says will halt future U.S. sales of insecticide
07/29DJTech Stocks Up On Google Earnings - Tech Roundup
07/29DJMERCK : Revenue Rises on Cancer, Hepatitis Treatments -- Update
07/29DJABBVIE : Results Boosted by Humira, Pipeline Growth
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/19 Midday Gainers / Losers
07/19 Dearth of white knights prompts SciClone to stay the course as independent fi..
06/17 After Hours Gainers / Losers
05/15 WEEK IN REVIEW : China Leads Global Pharma Innovation, Says Thomson Reuters
Duration : Period :
SciClone Pharmaceuticals,  Technical Analysis Chart | SCLN | US80862K1043 | 4-Traders
Full-screen chart
Technical analysis trends SCICLONE PHARMACE...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Friedhelm Blobel President, Chief Executive Officer & Director
Jon Sheldon Saxe Chairman
Wai-Shun Wilson Cheung Chief Financial Officer, Secretary & SVP-Finance
Rick J. Hawkins Independent Director
Gregg Anthony Lapointe Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON21.91%344 463
PFIZER INC.14.28%223 732
ROCHE HOLDING LTD.-9.99%218 231
NOVARTIS AG-5.30%215 109
MERCK & CO., INC.11.06%162 372
More Results